close

Fenwick & West Represents DexCom in $48M Public Offering

February 11, 2009

Fenwick & West recently represented client DexCom, Inc. (Nasdaq: DXCM) in its $48 million offering of 15,844,000 shares of its common stock priced at $3.00 per share. The offering closed on February 4, 2009, and Piper Jaffray & Co. acted as the sole manager of this offering.

DexCom, the San Diego, CA based leading developer of sensor technology for the continuous monitoring of glucose in people with diabetes, made its initial public offering in April 2005.

The Fenwick & West transaction team included corporate attorneys Robert Freedman, James Evans, Gaelen Gates and Robert Ricca.

To learn more about this transaction, please visit DexCom.com.


About Fenwick & West

Fenwick & West provides comprehensive legal services to technology and life sciences clients of national and international prominence. The firm is ranked by MergerMarket as one of the top five technology M&A practices in the U.S. and by Corporate Board Member as one of the top five corporate law firms in northern California for publicly traded companies.